{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:11:19Z","timestamp":1790871079957,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17016010"],"award-info":[{"award-number":["17016010"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21390147"],"award-info":[{"award-number":["21390147"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21591808"],"award-info":[{"award-number":["21591808"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.clim.2020.108457","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T17:36:38Z","timestamp":1588786598000},"page":"108457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["A phase I study of loco-regional immunotherapy by transbronchial injection of \u03b1-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer"],"prefix":"10.1016","volume":"215","author":[{"given":"Fumihiro","family":"Ishibashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Sakairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takekazu","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumitsu","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruaki","family":"Mizobuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehisa","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2020.108457_bb0005","first-page":"505","article-title":"The global burden of cancer 2013","volume":"4","year":"2015","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.clim.2020.108457_bb0010","article-title":"Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies","volume":"12","author":"Davies","year":"2017","journal-title":"Pros One"},{"key":"10.1016\/j.clim.2020.108457_bb0015","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/ni1203-1164","article-title":"The NKT cell system: bridging innate and acquired immunity","volume":"4","author":"Taniguchi","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0020","first-page":"5102","article-title":"Antitumor cytotoxicity mediated by ligand-activated human V\u03b124 NKT cells","volume":"59","author":"Kawano","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0025","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-\u03b3 production by invariant NK T cells in advanced cancer","volume":"167","author":"Tahir","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0030","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2020.108457_bb0035","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","article-title":"Increased intratumor V\u03b124-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas","volume":"11","author":"Tachibana","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0040","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20031462","article-title":"Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2","volume":"199","author":"Metelitsa","year":"2004","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.clim.2020.108457_bb0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","article-title":"Therapeutic activation of V\u03b124+V\u03b211+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity","volume":"103","author":"Nieda","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clim.2020.108457_bb0050","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of \u03b1-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.clim.2020.108457_bb0055","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1182\/blood-2012-06-435503","article-title":"Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma","volume":"121","author":"Richter","year":"2013","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.clim.2020.108457_bb0060","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0065","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2018.02021","article-title":"Clinical application of iNKT cell-mediated anti-tumor activity against lung Cancer and head and neck Cancer","volume":"9","author":"Takami","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0070","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","article-title":"A phase I study of \u03b1-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer","volume":"11","author":"Ishikawa","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0075","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1158\/1078-0432.CCR-06-0114","article-title":"A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer","volume":"12","author":"Motohashi","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0080","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of \u03b1-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0085","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1172\/JCI36264","article-title":"Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans","volume":"118","author":"De Santo","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2020.108457_bb0090","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"V\u03b124-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2020.108457_bb0095","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10875-012-9697-9","article-title":"Accumulation of activated invariant natural killer T cells in the tumor microenvironment after \u03b1-galactosylceramide-pulsed antigen presenting cells","volume":"32","author":"Nagato","year":"2012","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.126.1.122","article-title":"Real-time endobronchial ultrasound-guided transbronchial needle aspiration of mediastinal and hilar lymph nodes","volume":"126","author":"Yasufuku","year":"2004","journal-title":"Chest."},{"key":"10.1016\/j.clim.2020.108457_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-007-0373-5","article-title":"Phase I study of \u03b1-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer","volume":"57","author":"Uchida","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2020.108457_bb0110","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.99.3.562","article-title":"Safety of the transbronchial biopsy in outpatients","volume":"99","author":"Hernandez Blasco","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.clim.2020.108457_bb0115","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1349-7006.2009.01135.x","article-title":"Combination therapy of in vitro-expanded natural killer T cells and \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma","volume":"100","author":"Kunii","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2020.108457_bb0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.clim.2010.11.014","article-title":"Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy","volume":"138","author":"Yamasaki","year":"2011","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0125","first-page":"5245","article-title":"Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy","volume":"59","author":"Mukai","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF01517164","article-title":"Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte\/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha","volume":"38","author":"Young","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2020.108457_bb0135","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGF\u03b2","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0140","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2005.00.463","article-title":"Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas","volume":"23","author":"Mazzolini","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2020.108457_bb0145","first-page":"509","article-title":"Combination of direct intratumoral administration of dendritic cells and irradiation induces strong systemic antitumor effect mediated by GRP94\/gp96 against squamous cell carcinoma in mice","volume":"31","author":"Akutsu","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.clim.2020.108457_bb0150","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-\u03b3 production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2020.108457_bb0155","first-page":"285","article-title":"Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer","volume":"9","author":"Yu","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2020.108457_bb0160","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3349\/ymj.2005.46.6.835","article-title":"Combined treatment of an intratumoral injection of dendritic cells and systemic chemotherapy (paclitaxel) for murine fibrosarcoma","volume":"46","author":"Choi","year":"2005","journal-title":"Yonsei Med. J."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619307181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661619307181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:02:23Z","timestamp":1761494543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661619307181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":32,"alternative-id":["S1521661619307181"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2020.108457","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I study of loco-regional immunotherapy by transbronchial injection of \u03b1-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2020.108457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108457"}}